FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention describes tenatopazol (-)-enantiomer, i. e. (-)-5-methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl}imidazo[4,5-b]pyridine possessing the improved pharmacokinetic properties as compared with its (+)-enantiomer or racemic tenatoprazol, and a pharmaceutical composition containing thereof, and its using in treatment of digestive tract pathology.
EFFECT: improved and valuable medicinal properties of drug.
11 cl, 5 tbl, 1 ex
Authors
Dates
2007-11-20—Published
2003-12-16—Filed